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Abstract
Background: The pulmonary surfactant protein (SP)-A has potent immunomodulatory activities
but its role and regulation during allergic airway inflammation is unknown.
Methods: We studied changes in SP-A expression in the bronchoalveolar lavage (BAL) using a
murine model of single Aspergillus fumigatus (Af) challenge of sensitized animals.
Results: SP-A protein levels in the BAL fluid showed a rapid, transient decline that reached the
lowest values (25% of controls) 12 h after intranasal Af provocation of sensitized mice. Decrease
of SP-A was associated with influx of inflammatory cells and increase of IL-4 and IL-5 mRNA and
protein levels. Since levels of SP-A showed a significant negative correlation with these BAL
cytokines (but not with IFN-γ), we hypothesized that SP-A exerts an inhibitory effect on Th2-type
immune responses. To study this hypothesis, we used an in vitro Af-rechallenge model. Af-induced
lymphocyte proliferation of cells isolated from sensitized mice was inhibited in a dose-dependent
manner by addition of purified human SP-A (0.1–10 µg/ml). Flow cytometric studies on Af-
stimulated lymphocytes indicated that the numbers of CD4+ (but not CD8+) T cells were
significantly increased in the parental population and decreased in the third and fourth generation
in the presence of SP-A. Further, addition of SP-A to the tissue culture inhibited Af-induced IL-4
and IL-5 production suggesting that SP-A directly suppressed allergen-stimulated CD4+ T cell
function.
Conclusion: We speculate that a transient lack of this lung collectin following allergen exposure
of the airways may significantly contribute to the development of a T-cell dependent allergic
immune response.
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Background
Surfactant protein (SP)-A belongs to a family of innate
host defense proteins termed collectins because of the
presence of collagenous and also lectin-like domains [1].
SP-A has a potent immunomodulatory function with the
N-terminal and C-terminal portions of the molecule capa-
ble of either activating or suppressing functions of cells of
the immune system [2].
Allergen-induced asthma is characterized by the activa-
tion and steering of T-cells to a "helper" (Th) 2-type
inflammation with eosinophilia, high serum immu-
noglobulin (Ig) E levels, reversible airway obstruction and
hyper responsiveness (AHR) [3]. We have previously
shown that allergic AHR is associated with disruption of
surfactant biophysics, changes in the hydrophobic sur-
factant protein B and C [4] and upregulation of the lung
collectin SP-D [5,6].
While SP-A is the most abundant and most extensively
studied surfactant protein in the lung immune homeosta-
sis [7-9], it is unclear how this molecule is regulated or
functions during allergic inflammation. Published studies
have shown that SP-A can inhibit lymphocyte function in
vitro [10-12] and that administration of this protein in
murine models ameliorated allergic changes in the lung
[13-15], indicating a potential protective role. However,
its direct regulatory action has not been detailed. The
results of this study indicate specific changes in SP-A
expression during development of an allergen induced
immune response and show that SP-A can directly modu-
late the function of Th lymphocytes suggesting a regula-
tory link between innate and adaptive immunity in
allergic airway inflammation.
Methods
Murine model of Af sensitization
Sensitized mice were injected intraperitoneally (i.p.) with
20  µg of Af  (Hollister Stier, Elkhart, IN) and 20 mg
Al(OH)3 (Imject Alum; Pierce, Rockford, IL) in PBS (100
µl) on days 1 and 14, followed by intranasal (i.n.) chal-
lenge on day 27 with 25 µl of allergen extract: (12.5 µg Af
in 21% glycerol/ PBS). To analyze the kinetics of SP-A pro-
tein and mRNA changes BAL fluid and lung tissue were
collected before (0 h) and 1, 6, 12, 24, 48 and 72 h after
intranasal (i.n.) treatment, using a separate animal group
at each time point (n = 6 in each) as described previously
[4]. These time points were selected on the basis of our
previous experience with acute models of locally elicited
inflammation in mice [4,16,17]. Af sensitized and vehicle
challenged mice (n = 8), non sensitized, Af challenged
mice (n = 6) and non sensitized, glycerol challenged mice
(n = 8) were studied 12 h after treatment. Naïve mice (n =
8) were used to control for the effects of i.p. sensitization
and/or glycerol challenge. Lung function, BAL inflamma-
tory cell and cytokine profile and SP-A levels were not sig-
nificantly different between naïve animals and the groups
that received sensitization plus glycerol challenge or glyc-
erol challenge alone (not shown). All experimental sub-
jects in this study were under a protocol approved by the
Institutional Animal Care and Use Committee of the Uni-
versity of Pennsylvania.
Analysis of SP-A protein and mRNA expression
Lungs were lavaged with sterile saline as previously
described [4-6]. SDS-PAGE of the surfactant samples was
carried out using NuPAGE 10% Bis-Tris gels (Novex, San
Diego, CA). Western blots were performed using rabbit
polyclonal anti-SP-A. Each lane was loaded with 10 µg of
total protein. To investigate the absolute SP-A content in
the BAL in addition to Western blot analysis, we used an
ELISA protocol as described previously in detail [5]. Total
RNA was isolated from lungs and specific SP-A mRNA
content was determined by Northern blot analysis as
described previously [6,18].
Assessment of airway inflammation following intranasal 
challenge of Af-sensitized mice
In vivo measurement of lung function after Af challenge
was performed in conscious, unrestrained, spontaneously
breathing mice in a whole-body plethysmograph (Buxco
Electronics Inc., Troy, NY) as described previously [4]. Air-
way function was quantified using the Enhanced Pause
(Penh).
Analysis of total and differential cell count and cytokine
profile of the BAL was carried out after lungs were lavaged
with sterile saline as previously published [4,6,19].
Cytokine levels were measured in the cell free supernatant
of the BAL by ELISA using antibodies and recombinant
cytokines from PharMingen (San Diego, CA).
Preparation of SP-A
Human SP-A was purified from human surfactant col-
lected previously from patients with pulmonary alveolar
proteinosis (PAP) as previously published [20]. The puri-
fied material was analyzed for protein concentration, sub-
jected to Coomassie Blue staining (Figure 4A) and
Western blot analysis (Figure 4B) and stored in aliquots at
-80°C. The biological activity of the purified SP-A was
tested in stimulated human peripheral blood monocytes
(PBMC) (Figure 4C).
Cell Proliferation Assays
Mice were sacrificed and spleens were harvested 24 hours
after treatment. Spleens were homogenized in 10 mL of
sterile PBS and layered over 5 mL of Histopaque (Histo-
paque-1077, Sigma) followed by density gradient centrif-
ugation at 400 × g for 30 minutes at 18°C. Cells were thenRespiratory Research 2005, 6:97 http://respiratory-research.com/content/6/1/97
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SP-A has a significant inhibitory effect on antigen specific lymphocyte proliferation from mice sensitized and challenged with Af Figure 4
SP-A has a significant inhibitory effect on antigen specific lymphocyte proliferation from mice sensitized and challenged with Af. 
(A): Baseline (unstimulated) proliferation of splenic lymphocytes. Endotoxin in concentration equivalent to the endotoxin con-
tent of the 10 µg/ml SP-A samples did not affect cell proliferation. (B): In vitro Af stimulated proliferation of cells from mice sen-
sitized and challenged with Af was inhibited by presence of SP-A, in a dose-dependent manner. (C): The Af dose-response curve 
of sensitized lymphocytes was abrogated in the presence of SP-A (10 µg/ml). (D) Presence of SP-A inhibited murine lym-
phocytes stimulated with PMA (2 ng/ml) and ionomycin (100 ng/ml). Background cpm (from wells that contain no cells): 0–16. 
Mean ± SEM of n = 4 independent experiments presented, each performed in triplicates. * p < 0.05: 0 vs. 10 µg/ml
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washed and cultured at 2 × 106 cells ml-1 in U-bottom 96-
well plates (Nunclon Delta Surface, Nunc, Denmark).
Af  and PMA-Ionomycin (PI, Sigma-Aldrich, St. Louis,
MO) were used as mitogens for the lymphocyte prolifera-
tion assay. Varying amounts of SP-A were added to stimu-
lated lymphocytes. Mouse splenocyte cultures were
incubated for 37°C in a humidified atmosphere with 5%
CO2 for 96 h. At the 72 h time point, each well was pulsed
with [3H] thymidine (0.2 mCi ml-1) for an additional 24
h at 37°C. Cells were then harvested on a PHD Harvester
(Cambridge Technology, Cambridge, MA). [3H] thymi-
dine incorporation was determined via liquid scintillation
counting (Beckman Instruments, New York, NY). Samples
were plated in triplicates and the experiments were
repeated n = 4 times unless otherwise stated.
Human peripheral blood mononuclear cells were isolated
from healthy volunteers using a standard protocol
approved by the IRB of the University of Pennsylvania.
Flow cytometric analysis of lymphocytes
The effects of SP-A on lymphocyte proliferation was fur-
ther assessed using CFSE labeling as previously described
[21]. Surface staining was performed at the time of harvest
using Phycoerythin conjugated anti-mouse CD3, Fluo-
rescin (FITC) conjugated anti-mouse CD4, FITC conju-
gated rat IgG2b isotype control (all from Pharmingen) and
Allophycocyanin conjugated anti-human CD8 (Caltag,
Burlingame, CA). Data were acquired on a four-color,
dual laser FACSCalibur (Becton Dickinson, San Jose, CA).
For FACS analysis the gated cell populations were divided
into four different generations (G1, G2, G3 and G4)
according to their CFSE content. Isotype controls were
used to distinguish positive and negative populations. The
SP-A-treated samples were compared with, and data were
expressed as the percentage of the non-treated samples.
Interleukin (IL)-4, IL-5 and IFN-γ assays
Real time PCR
A relative quantitation of lung IL-4, IL-5, and IFN-γ mRNA
expression was performed by real time PCR using Taq-
Man(R) Gene Expression Assay and TaqMan(R) Universal
PCR Master Mix: Mm00445259, Mm00439646,
Mm00434204, and Mm00801778, respectively, (Applied
Biosystems) according to the manufactures instructions.
In brief three RNA samples isolated from the lungs per
time points, were reverse transcribed using Super-
script(TM) III First Strand Synthesis System (Invitrogen).
Approximately 100 ng of cDNA was used per singleplex
PCR reaction in a total volume of 25 µl. Cycling was per-
formed on an ABI SDS-7000 and ABI SDS-7500 respec-
tively with an initial denaturation step at 95°C for 10 min
and 40 cycles of 15 sec. at 95°C and 1 min. at 60°C. Every
sample was run in triplicate and β-2-microglobin
(Mm00437762) was used as endogenous control. The
Comparative Ct Method was used to analyze the results
using ABI PRISM(R) 7900 SDS software. Results are
expressed as fold difference (with range incorporating the
standard deviation of the ddCt value into the fold differ-
ence calculation) relative to naïve animals.
In vitro release of cytokines from cultured lymphocytes
Splenic lymphocytes were cultured for 48 h as described.
The supernatant was then removed and frozen at -80°C
pending analysis. OptEIA mouse IL-4, IL-5 and IFN-γ
ELISA kits (Pharmingen) were used.
Data analysis
Data were expressed as mean ± SEM. Time courses and
dose responses were compared using ANOVA. To test dif-
ferences between individual groups Student's t test assum-
ing equal variances were performed. Correlations were
investigated by regression analysis. A p value of < 0.05 was
considered as significant. Data were analyzed with the
Sigma Stat standard statistical package (Jandel Scientific).
Results
Allergic sensitization and challenge of Balb/c mice with Af 
induced a transient fall in the levels of SP-A in the BAL fluid
To study the relationship between changes in SP-A levels
and the sequence of inflammatory events we used a model
of single allergenic airway provocation [4]. Western blots
were analyzed from the cell-free supernatant of the BAL
fluid, using naïve control samples as standards that were
run on each gel. Decreases in SP-A levels began at 1 h (88
± 19% of naïve control) and reached the lowest values 12
h (26 ± 5%) after Af challenge. Recovery was observed 72
h later (135 ± 40 %) (Fig. 1A and 1B). To verify that the
alterations in SP-A levels were specific at the 12 h time
point, sensitized and Af-challenged mice (26.5 ± 5%)
were compared with mice that received vehicle (glycerol)
treatment instead of antigen (90.0 ± 19%; p < 0.05 n = 8,
Fig 1C).
SP-A protein decreases were not associated with commen-
surate mRNA changes. Northern blot analysis on RNA
extracted from the lung tissue of each group of sensitized
mice showed that SP-A mRNA actually increased 12 h
after allergen challenge in comparison with the 0 h con-
trols (160 ± 6% vs. 106 ± 16 p < 0.05, n = 5, Fig 1B). The
absolute BAL SP-A content (determined by ELISA) was
decreased from 378 ± 46 to 239 ± 25 µg/lung (p < 0.05 n
= 8) at 12 h and to 222 ± 22 µg/lung (p < 0.05 n = 8) 48
h after Af challenge.Respiratory Research 2005, 6:97 http://respiratory-research.com/content/6/1/97
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Decreased SP-A is associated with allergic airway 
inflammation to Af 12 h after allergen provocation of 
sensitized mice
In order to examine the proinflammatory changes that
were linked with the greatest fall in SP-A concentrations,
we chose to study the 12 h time point. Following allergen
provocation there were significant Penh increases 12 h
after Af-challenge of sensitized mice (1.91 ± 0.36, n = 8)
in comparison with glycerol challenge (0.88 ± 0.06, n = 8,
p < 0.01). The glycerol challenge controls were not differ-
ent from mice that received no sensitization or challenge
(Fig 2A). Levels of Penh returned to near normal by 72 h
(1.36 ± 0.1; n = 8). The cellular composition of BAL
showed that 12 h after intranasal Af challenge there was a
significant influx of inflammatory cells predominated by
neutrophils (500 × 103 cells, p < 0.01, n = 8) and eosi-
nophils (110 × 103 cells p < 0.01, n = 8) in comparison
with glycerol challenged controls. These cell numbers
were also reduced (1 ± 1 and 31 ± 19, respectively, n = 8)
by the 72 h time point.
Allergen challenge of sensitized mice with Af induced a transient decrease in the BAL SP-A protein levels Figure 1
Allergen challenge of sensitized mice with Af induced a transient decrease in the BAL SP-A protein levels. (A) SP-A Western 
blots from two representative samples of BAL obtained 1, 6, 12, 24, 48 and 72 h after Af challenge. (B): SP-A protein from BAL 
(open circles) and lung tissue mRNA (closed circles); % of the naïve control values; n = 4–6. (C): SP-A protein levels measured 
12 h after Af challenge Mean ± SEM of n = 8 each; ** p < 0.01 (Af/Af vs. Af/gly).
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Single intranasal provocation of sensitized mice with Af induced increase in Penh, inflammatory cell influx and Th2 but not Th1  cytokine release, 12 h After intranasal challenge Figure 2
Single intranasal provocation of sensitized mice with Af induced increase in Penh, inflammatory cell influx and Th2 but not Th1 
cytokine release, 12 h After intranasal challenge. (A): Lung function measured by Penh. (B): BAL total and differential cell counts 
were used to calculate the absolute cell number. MP: macrophages EP: eosinophils, NP: neutrophils, LC: lymphocytes. (C): BAL 
Cytokine levels measured by ELISA (pg/ml). Mean ± SEM of n = 8 each; ** p < 0.01 (Af/Af vs. Af/gly) (D): Lung tissue cytokine 
mRNA levels measured by real-time PCR (fold increase in comparison to naïve control levels). ** p < 0.01 (vs. 0 h)
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Similarly to our previously characterized ovalbumin and
Af-induced models of allergic airway inflammation
[4,6,19], i.p. sensitization and i.n. Af challenge induced a
local production of predominantly Th2-type cytokines. In
comparison with glycerol challenged controls there was a
significant release of IL-4 (559 pg/ml vs. 3 pg/ml p < 0.01),
IL-5 (283 pg/ml vs. 10 pg/ml p < 0.001; Figure 2C) and
Eotaxin (173 pg/ml vs. 10 pg/ml p < 0.001) but not IFN-
γ 12 h after allergen challenge (Figure 2C). Regression
analysis using data pooled from the sensitized/Af chal-
lenged, sensitized glycerol challenged and non sensitized
glycerol challenged mice revealed a significant, negative
correlation with each of these cytokines (SP-A vs. IL-4: r =
-0.61, p < 0.05; SP-A vs. IL-5: r = -0.82, p = 0.01; SP-A vs.
Eotaxin: r = -0.75, p < 0.01). There was no correlation
between SP-A and IFN-γ (not shown). Further, by the 72
h time point after allergen challenge IL-4 (8.7 ± 2.7 pg/
ml), IL-5 (10.3 ± 7.3 pg/ml) and Eotaxin (9.72 ± 3.5 pg/
ml) returned to close to baseline. To verify that the
amount of airway SP-A is negatively associated with Th2
cytokine production, we also performed quantitative real-
time PCR analysis of IL-4, IL-5 and IFN-γ mRNA. These
results showed that mRNA levels for the Th2 cytokines
increased approximately 35 fold in comparison with
naïve controls 12 h after allergen challenge and returned
to control levels by 72 h (Figure 2D).
SP-A inhibits allergen-driven proliferation of lymphocytes 
in vitro
To test the hypothesis that SP-A exerts an inhibitory effect
on Th2 processes, we used a model of in vitro allergen re-
challenge of lymphocytes isolated from sensitized and
control mice and treated the cells with SP-A purified from
human PAP material. Figure 3 shows that following puri-
fication and endotoxin depletion the structural integrity
(Fig 3A) and immunogenicity (Fig 3B) of SP-A remained
intact. Purified, LPS-depleted human SP-A exhibited sig-
nificant biological activity as assessed by its effects on pro-
liferation of human PBMC (Fig 3C).
Splenic lymphocytes isolated from naïve mice and mice
sensitized with Af were re-challenged in vitro with Af in the
presence or absence of SP-A. 3H-thymidine uptake was
expressed as cpm (counts per minute). The background
cpm throughout our experiments ranged between 0 and
16. The SP-A preparation had < 0.07 endotoxin units/ml.
This level is consistent with other cell culture SP-A prepa-
rations [10]. Furthermore, culturing murine lymphocytes
in up to twice the amount of LPS (0.14 endotoxin units/
ml) had no significant effect on lymphocyte function (Fig
4A). Baseline proliferation of naïve lymphocytes was not
affected by SP-A (Figure 4A). It appears that an activated
state of the lymphocytes is a prerequisite for inhibition by
SP-A since sensitized cells stimulated with Af were mark-
edly inhibited by SP-A in a dose-dependent manner (Fig
4B). Indeed greater antigenic stimulation resulted in
greater suppression of proliferation by SP-A at 10 µg/ml
(Fig 4C).
Suppression of T cell proliferation was not a result of
sequestering Af in the culture because lymphocytes stimu-
lated with PMA (10 ng/ml) and ionomycin (500 ng/ml)
were inhibited by SP-A (10 µg/ml) to a similar extent as
the Af-stimulated lymphocytes by 66 ± 4% (Figure 4D),
suggesting a direct inhibitory action on activated cells.
Purification and biological activity of SP-A from human PAP material Figure 3
Purification and biological activity of SP-A from human PAP material. (A): Coomassie Blue staining. (B): Western blot compari-
son of endotoxin-depleted (ED) SP-A preparations (1 µg) with human PAP material (1 µg) used as a positive control. (C): Effect 
of purified human SP-A on normal human PBMC proliferation. Cells were stimulated with PMA (2 ng/ml) and ionomycin (100 
ng/ml). Stimulation Index (cpm of stimulated cells divided by cpm of corresponding unstimulated cells). Mean ± SEM of n = 12
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SP-A inhibits Af-induced CD3/CD4+ Th2 cell function
To further confirm the effects of SP-A on the proliferating
cells, we added an intracellular fluorescent dye 5,6-car-
boxy- fluorescein diacetate succinimidyl ester (CFSE) to
the cell cultures. The amount of this dye is halved as the
Af-stimulated lymphocytes divide, allowing individual
generations to be detected using FACS analysis. Mononu-
clear cells were gated for positive CD3/CD4 or CD3/CD8
expression and marked as G1 (the highest CFSE content),
G2, G3 and G4 population according to decreasing levels
of CFSE expression. Cells incubated in the presence of 10
µg/ml of SP-A were compared with equivalent popula-
tions of cells stimulated in the absence of SP-A and the
results are expressed as a percentage of the SP-A-free
(100%) control. In comparison with medium treatment,
(represented by the middle line) addition of SP-A
increased the proportion of cells that remained in the G1
population in the samples stimulated by Af (Figure 5A).
The proportion of the G1 cells in the SP-A treated CD3/
CD4 populations were 95%, 118%, and 163% of the
medium treated (SP-A-free) controls at 0, 1 and 10 µg/ml
Af  concentration, respectively. Thus, cells exposed to
greater antigen stimulation appeared to be more suscepti-
ble to inhibition by SP-A. We did not observe a similar
inhibitory effect by SP-A in the CD3/CD8 cells (not
shown).
Addition of SP-A (10 µg/ml) to sensitized lymphocytes
significantly inhibited IL-4 and IL-5 production both in
the Af-induced (Figure 5B) and PMA/ionomycin stimu-
lated (not shown) cultures (p < 0.05, n = 4). SP-A appar-
ently also inhibited IFN-γ levels in the non-stimulated and
in the PMA/ionomycin stimulated samples indicating a
non-selective activity on cytokine production by stimu-
lated T cells (not shown).
Discussion
Emerging evidence suggests that collectins provide a link
between innate and adaptive immunity. The relationship
of SP-A production to inflammatory changes in the lung
however is poorly defined. This study reports that a tran-
sient decrease in airway SP-A levels is associated with
mRNA transcription and release of Th2-type cytokines fol-
lowing allergen provocation. The results also demonstrate
that this lung collectin has a direct negative regulatory
effect on allergen-induced lymphocyte activation in vitro.
Studies investigating allergen-induced airway inflamma-
tion previously described either significant increases
[22,23] or decreases of this surfactant protein [24]. One
reason for the conflicting data may be that levels of SP-A
undergo transitional changes during development of
allergic inflammation. Our time course study confirmed
that levels of SP-A in the BAL dramatically decreased to
SP-A inhibited Af-induced CD4+ T cell proliferation and release of IL-4 and IL-5 Figure 5
SP-A inhibited Af-induced CD4+ T cell proliferation and release of IL-4 and IL-5. (A): SP-A (10 µg/ml) increased the number of 
cells in the G1 (black bars) and decreased them in the G3-G4 populations of CD3/CD4+  lymphocytes (% change from the 
medium-treated samples). Average of 3 independent experiments. (B): Af-induced production of IL-4 and IL-5 by sensitized 
lymphocytes (S/Medium) was reduced in the presence of 10µg/ml of SP-A (S/SP-A) to levels similar to naïve lymphocytes (N/
Medium).  Lymphocytes were stimulated by Af (1 µg/ml). IL-4 (grey bars), IL-5 (white bars) and IFN-γ (black bars). * p < 0.05 S/
SP-A vs. S/Medium. Mean ± SEM of n = 4 experiments performed in triplicates..
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25% of the original 12 h after Af challenge but completely
recovered 72 h later. The exact mechanisms that regulate
the changes of SP-A concentrations in the airways are
uncertain. Since reduction in the absolute amounts of SP-
A was only 42%, the effect of dilution by the extravasated
plasma proteins 12 h after allergen challenge could have
significantly added to the fall in the fractional SP-A con-
centrations. Nevertheless, while further studies are needed
to unravel its intricate regulation [25], it appears that an
early decrease in the airway SP-A protein levels is not
compensated immediately by enhanced synthesis or
release, creating a relative, transient deficiency in this
protein.
SP-A changes were comparable to that of SP-B and SP-C,
described previously in a similar model [4]. Interestingly,
while SP-B and SP-C protein levels in the BAL closely
matched their respective mRNA recovered from the lung
tissue, the fall SP-A protein was not paralleled by mRNA
decreases. Thus (unlike in SP-B and SP-C), there is a dis-
sociation between SP-A mRNA and protein regulation
during the acute phase of an inflammatory response in the
lung. Such discrepancy was also observed in a study look-
ing at the effects of secretagogue-induced stimulation of
SP-A synthesis [26] and in an in vitro model where SP-A
mRNA but not protein expression was induced by dexam-
ethasone, cyclic AMP and IL-4 [27]. In addition to not
promptly following changes in mRNA production, SP-A
did not require constitutive protein synthesis indicating a
long intracellular half life [27]. Taken together, our previ-
ous and current work suggests that there is a significant lag
between transcriptional, translational and/or secretory
processes in SP-A regulation. Although the implications of
such SP-A deficiency are unclear, the regulatory effects on
the adaptive immune function during development of an
inflammatory response could be significant.
The inverse association we observed between levels of SP-
A and the inflammatory changes 12 h after allergen prov-
ocation was used to generate our hypothesis that SP-A
negatively regulates Th2 cytokine production. This
hypothesis was then tested by directly adding SP-A to
allergen-stimulated T cells. These results are in support of
previous reports showing that administration of SP-A alle-
viated allergic inflammatory changes in mice (reviewed in
[15]), however the underlying mechanisms remain
unclear. Binding of inhaled allergens such as particles of
Af [28,29] and house-dust mite [30] may be one way to
interfere with the allergic response. A second mechanism
could be an interference with the function of inflamma-
tory effector cells as indicated by inhibitory effects of SP-A
on chemokine release by activated eosinophils [13,31].
Further, recent research has highlighted the role of SP-A
on adaptive immune functions such as antigen presenta-
tion by dendritic cells [32] and T cell activation [10-12].
SP-A inhibited T-cell proliferation induced by various
non-specific stimulators through both an IL-2 independ-
ent and an IL-2 and T cell receptor dependent manner
[12].
The mechanism of T cell susceptibility to inhibition by SP-
A needs further clarifications. While the inhibitory effects
of SP-A have been demonstrated in antigen-stimulated
human PBMC [33] and more recently, in a murine system
of splenocytes co-cultured with ovalbumin-specific T cell
hybridomas [12], no study has examined the effect of SP-
A on T cell proliferation in a mouse model of allergen-
induced asthma in vitro. Here we present for the first time
the inhibitory effects of SP-A on generational progression
of sensitized lymphocytes to Af re-challenge in vitro. We
show that this inhibition was dose-dependent. Further,
inhibition of lymphocyte activation by SP-A was not due
to toxic effects since baseline proliferation of the lym-
phocytes was not affected. In addition, Figure 5A demon-
strates that CD3+/CD4+ lymphocytes had significantly
inhibited proliferative ability (as measured by the CFSE
content of the cells) in the presence of SP-A. In this FACS
analysis study the dead cells were excluded and only the
live cells were analyzed (an equal number of 10,000
events collected in every sample). These results suggest
that SP-A has a direct effect in suppressing proliferation of
cells. Previous studies similarly showed that neither SP-A
nor SP-D affects cell viability or apoptosis in PMA and
ionomycin-stimulated cells [12]. Similarly to a study
using cells from human asthmatics [33], we also showed
that the inhibitory effect of SP-A did not depend on inter-
ference with the antigen-T cell receptor interaction since it
suppressed both antigen- and mitogen-stimulated models
of proliferation. Our studies however further indicated
that in antigen-stimulated cultures sensitized cells
exposed to greater antigen concentration and thus
induced to proliferate more vigorously, were more suscep-
tible to inhibition by SP-A. In addition, in the presence of
SP-A there were significantly more sensitized CD4+ (not
CD8+) lymphocytes in the parental (G1) population at
higher  Af  concentrations, confirming that the antigen-
responsive, stimulated T helper cell population is the tar-
get of SP-A.
The effects of SP-A treatment on inhibiting Th2 cytokines
were previously studied ex vivo [34]. Here we show that
greater amount of airway SP-A was associated with a lesser
extent of Th2 cytokine release in vivo and that there was a
significant, negative correlation between SP-A and the
amount of IL-4, IL-5 and eotaxin supporting the hypothe-
sis that this collectin exerts an inhibitory effect on Th2
processes. Indeed addition of SP-A abolished production
of the Th2 cytokines IL-4 and IL-5 by Af-stimulated lym-
phocytes. Thus, SP-A may act as a natural immunosup-Respiratory Research 2005, 6:97 http://respiratory-research.com/content/6/1/97
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pressant in the lung with direct inhibitory actions on
allergen-stimulated CD4+ Th2 lymphocytes.
Conclusion
A transient decrease in airway levels of SP-A was associ-
ated with transcription of mRNA and release of the Th2-
type cytokines IL-4 and IL-5 but not IFN-γ. On the other
hand, addition of SP-A to lymphocyte cultures from sen-
sitized mice suppressed allergen-induced Th2-type
immune response. We speculate that this lung collectin
may play a protective role to prevent allergen-inhalation
provoked immune reactions and propose the novel con-
cept that a transient SP-A deficiency contributes to the
pathogenesis of the allergic airway response.
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